Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Change in Accured Expenses (2017 - 2025)

VYNE Therapeutics' Change in Accured Expenses history spans 9 years, with the latest figure at -$6.4 million for Q2 2025.

  • For Q2 2025, Change in Accured Expenses fell 281.99% year-over-year to -$6.4 million; the TTM value through Jun 2025 reached -$5.8 million, down 245.59%, while the annual FY2025 figure was -$12.3 million, 304.74% down from the prior year.
  • Change in Accured Expenses reached -$6.4 million in Q2 2025 per VYNE's latest filing, down from -$2.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $3.5 million in Q2 2024 to a low of -$9.6 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is -$822166.7, with a median of -$217500.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: plummeted 4782.93% in 2022, then soared 1072.73% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$2.8 million in 2021, then surged by 188.71% to $2.5 million in 2022, then plummeted by 60.61% to $993000.0 in 2023, then surged by 121.55% to $2.2 million in 2024, then plummeted by 391.18% to -$6.4 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Change in Accured Expenses are -$6.4 million (Q2 2025), -$2.5 million (Q1 2025), and $2.2 million (Q4 2024).